Jerusalem, 24 July, 2025 (TPS-IL) — Israel’s Innocan Pharma has filed a registration statement with the U.S. Securities and Exchange Commission for a planned public offering. The offering will include units made up of one common share and one warrant to buy a share later.

Based in Herzliya, Innocan develops CBD-based drugs and wellness products.

Innocan has applied to list its shares and warrants on the Nasdaq under the symbols “INNP” and “INNPW.” ThinkEquity will manage the offering.